Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Construction in Progress of $1.3 billion for Q2 2026, down 26.41% year-over-year from $1.8 billion in Q2 2025, and down 15.9% quarter-over-quarter from $1.5 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Construction in Progress for 12 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Construction in Progress fell 26.41% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $1.3 billion (down 26.41% YoY), while the FY2025 annual figure was $1.6 billion, up 6.16% from the prior year.
- Construction in Progress slipped to $1.3 billion in Q2 2026 per CELG-RI's latest filing, from $1.5 billion in the prior quarter.
- Across five years, Construction in Progress topped out at $1.8 billion in Q2 2025 and bottomed at $800.0 million in Q1 2022.
- Historically, Construction in Progress has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Construction in Progress soared 54.14% — and 2026, when it declined 26.41%.
- Bristol Myers Squibb's Construction in Progress stood at $1.1 billion in 2022, then increased by 2.09% to $1.1 billion in 2023, then surged by 41.86% to $1.5 billion in 2024, then increased by 6.16% to $1.6 billion in 2025, then fell by 19.95% to $1.3 billion in 2026.
- Business Quant data shows CELG-RI's Construction in Progress at $1.3 billion in Q2 2026, $1.5 billion in Q1 2026, and $1.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | - |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | - |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | - |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.62 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 973.00 Mn |
| Jun 30, 2022 | 850.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 764.00 Mn |
| Sep 30, 2021 | 695.00 Mn |